TrialAmerican journal of clinical dermatology2024

Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.

Amy S Paller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.